U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07176286) titled '18F-mFBG Uptake in Lewy Body Dementia' on Sept. 10.
Brief Summary: This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.
Study Start Date: Oct. 30
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease (PD)
Lewy Body Dementia (LBD)
Int...